Ticagrelor 90 mg vs ASA 100 mg: Number of Participants by Severity of Stroke and Overall Disability
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.168 | 0.159 | 0.177 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.181 | 0.172 | 0.19 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0126 | -0.0256 | 0.000318 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.93 | 0.863 | 1 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.916 | 0.837 | 1 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Ticagrelor 90 mg than on ASA 100 mg | 79.2 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Ticagrelor 90 mg | Ticagrelor 90 mg twice daily (BD) | 1,107 | 6,589 | OG000 | ClinicalTrials.gov |
| Group 2 | ASA 100 mg | ASA 100 mg once daily (OD) | 1,194 | 6,610 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants by Severity of Stroke and Overall Disability | ClinicalTrials.gov |
| Description | Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~1. \- No significant disability. Able to carry out all usual activities, despite some symptoms.~2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~3. \- Moderate disability. Requires some help, but able to walk unassisted.~4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~6. \- Dead.~Disability defined as mRS \> 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables. | ClinicalTrials.gov |
| Time frame | From randomization up to 97 days | ClinicalTrials.gov |
| Population | The population was the full analysis set which included all randomized patients. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] | ClinicalTrials.gov |
| NCT number | NCT01994720 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Acute Ischaemic Stroke, Transient Ischaemic Attack | ClinicalTrials.gov |
| Interventions | ticagrelor, Acetylsalicylic acid (ASA) | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2017-06-12 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01994720?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.